MRNA | Moderna, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	36.41 - 38.22
52 Week Range	35.80 - 170.47
Beta	1.29
Implied Volatility	87.56%
IV Rank	98.44%
Day's Volume	7,279,167
Average Volume	6,382,934
Shares Outstanding	384,818,000
Market Cap	14,215,176,920
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-12-07

Valuation
Profitability
Growth
Health
P/E Ratio	-6.36
Forward P/E Ratio	-40.02
EPS	-5.81
1YR Price Target	200.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	5,600
Country	USA
Website	MRNA

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

MRNA's peers: CVAC, NVAX, CWBR, RETA, OCEA, ENVB, HEPA, ELEV, AVRO, RAIN, KRYS, NTLA, EDIT, VRTX, BEAM, DNA, NVO

*Chart delayed

Analyzing fundamentals for MRNA we got that it has average fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is very good and Health is strong. For more detailed analysis please see MRNA Fundamentals page.

Watching at MRNA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on MRNA Technicals page.